Virological characteristics of the SARS-CoV-2 XEC variant.

Autor: Kaku Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Okumura K; Faculty of Liberal Arts, Sophia University, Tokyo, Japan., Kawakubo S; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Chen L; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan., Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Uwamino Y; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan., Begum MM; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Leong S; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address: KeiSato@g.ecc.u-tokyo.ac.jp.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Nov 06. Date of Electronic Publication: 2024 Nov 06.

Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.

Autor: Kuwata T; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: tkuwata@kumamoto-u.ac.jp., Kaku Y; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Biswas S; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Matsumoto K; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Shimizu M; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Kawanami Y; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Uraki R; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Okazaki K; Department of Analytical and Biophysical Chemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Minami R; Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan., Nagasaki Y; Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan., Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Yoshida I; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Ito M; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Kiso M; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Yamayoshi S; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Imai M; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Toyoda M; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Ueno T; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Inoue T; Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Japan., Tanaka Y; Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Kimura KT; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan., Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan., Sugita Y; Laboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan., Noda T; Laboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan., Morioka H; Department of Analytical and Biophysical Chemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Kawaoka Y; Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Matsushita S; Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: shuzo@kumamoto-u.ac.jp.

Publikováno v: EBioMedicine [EBioMedicine] 2024 Nov 01; Vol. 110, pp. 105439. Date of Electronic Publication: 2024 Nov 01.

Sewage surveillance of SARS-CoV-2 in Tokyo (May 2020-June 2022): method using high-throughput, fully-automated platform.

Autor: Kumagai R; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Kawakami M; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Kasuya F; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Yamada K; Bureau of Sewerage, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Takahashi A; Bureau of Sewerage, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Murayama K; Bureau of Sewerage, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Morita K; Bureau of Sewerage, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Kaneyasu T; Bureau of Waterworks, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Tamai N; Bureau of Waterworks, Tokyo Metropolitan Government, 2-8-1, Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 163-8001 Japan., Hasegawa M; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Harada S; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Amano A; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Fujiwara T; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Miyake H; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Nagashima M; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan., Sadamasu K; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-Cho, Shinjuku-Ku, Tokyo, 169-0073 Japan.

Publikováno v: Virusdisease [Virusdisease] 2024 Sep; Vol. 35 (3), pp. 520-524. Date of Electronic Publication: 2024 Jul 02.

Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.

Autor: Tsujino S; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan., Deguchi S; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan., Nomai T; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan., Padilla-Blanco M; First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia.; Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU (UCH-CEU), CEU Universities, Valencia, Spain., Plianchaisuk A; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Wang L; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan., Begum MM; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Mizuma K; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Nao N; One Health Research Center, Hokkaido University, Sapporo, Japan.; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan., Kojima I; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Tsubo T; One Health Research Center, Hokkaido University, Sapporo, Japan., Li J; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Matsumura Y; Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Nagao M; Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Oda Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan., Tsuda M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan., Anraku Y; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan., Kita S; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan., Yajima H; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan., Sasaki-Tabata K; Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan., Guo Z; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Hinay AA Jr; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Yoshimatsu K; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan., Yamamoto Y; HiLung Inc., Kyoto, Japan., Nagamoto T; HiLung Inc., Kyoto, Japan., Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Nasser H; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt., Jonathan M; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Putri O; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Biomedicine, School of Life Sciences, Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia., Kim Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Life Sciences, Faculty of Natural Science, Imperial College London, London, UK., Chen L; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan., Suzuki R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan., Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; One Health Research Center, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan., Maenaka K; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan., Irie T; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Matsuno K; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; One Health Research Center, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan., Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan., Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Takayama K; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan., Zahradnik J; First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia., Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.; CREST, Japan Science and Technology Agency, Kawaguchi, Japan., Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.; One Health Research Center, Hokkaido University, Sapporo, Japan.; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan., Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

Publikováno v: Microbiology and immunology [Microbiol Immunol] 2024 Sep; Vol. 68 (9), pp. 305-330. Date of Electronic Publication: 2024 Jul 04.

Genetic characteristics of invasive pneumococcal disease-derived Streptococcus pneumoniae of serogroup 24 isolated in Tokyo, Japan.

Autor: Uchitani Y; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan. Electronic address: Yumi_Uchitani@member.metro.tokyo.jp., Okuno R; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan., Ariyoshi T; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan., Kubota H; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan., Suzuki J; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan., Sadamasu K; Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, 169-0073, Japan.

Publikováno v: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.